Physician profile
Bruce G Roy
NPI 1538187018
$28,573.41
in general payments reported to CMS, 2019-2025
51 companies · $6,163 in 2025
The $6,163 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,720 · 2020: $2,210 · 2021: $3,612 · 2022: $3,852 · 2023: $4,345 · 2024: $5,671 · 2025: $6,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,664.99 |
| Education | $513.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,451.70 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $3,401.47 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,282.11 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $1,929.57 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $1,488.35 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Jazz Pharmaceuticals INC. | $1,296.82 | 2019-2025 | |
| Grifols USA, LLC | $1,290.44 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $1,187.27 | 2021-2025 | Glassia, Cuvitru, Hyqvia |
| Insmed, INC. | $1,104.49 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $1,066.37 | 2019-2025 | |
| Harmony Biosciences LLC | $873.19 | 2020-2025 | Wakix |
| Philips North America LLC | $716.32 | 2019-2025 | Vest Therapy Und |
| Paratek Pharmaceuticals, INC. | $693.26 | 2021-2025 | Nuzyra |
| Inspire Medical Systems, INC. | $425.58 | 2022-2025 | Inspire |
| Mylan Specialty L.P. | $383.15 | 2019-2024 | Yupelri |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $380.51 | 2019-2025 | Smartvest |
| United Therapeutics Corporation | $369.36 | 2021-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $365.31 | 2019-2024 | |
| Axsome Therapeutics, INC. | $364.03 | 2022-2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $328.41 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $294.36 | 2023-2025 | Lumryz |
| Genentech USA, INC. | $279.68 | 2019-2023 | Xolair |
| Mallinckrodt Hospital Products INC. | $276.13 | 2024-2025 | Acthar |
| Merck Sharp & Dohme LLC | $219.56 | 2021-2025 | Winrevair, Zerbaxa, Recarbrio |
| Amgen INC. | $204.91 | 2022-2025 | Tezspire, Tavneos |
| Intuitive Surgical, INC. | $192.06 | 2024 | |
| Verona Pharma, INC. | $181.28 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $176.50 | 2019-2023 | |
| Viatris Specialty LLC | $163.27 | 2025 | Yupelri |
| Baxter Healthcare | $139.83 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $124.04 | 2025 | Zepbound |
| Ambu INC. | $115.50 | 2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Sunovion Pharmaceuticals INC. | $98.28 | 2019-2020 | |
| Advanced Respiratory, INC | $86.00 | 2019-2021 | |
| Shire North American Group INC | $77.96 | 2019 | |
| Novo Nordisk INC | $63.02 | 2024-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $58.07 | 2021 | |
| Circassia INC. | $49.69 | 2019 | |
| Itamar Medical INC | $40.49 | 2023 | Watchpatone |
| Azurity Pharmaceuticals, INC. | $36.53 | 2025 | Alvesco |
| Optinose US, INC. | $34.27 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $33.42 | 2023 | Quviviq |
| Cvrx, INC. | $24.07 | 2025 | Barostim Neo System |
| Axonics, INC. | $19.43 | 2024 | Axonics |
| Pulmonx Corporation | $18.07 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Resmed Corp | $15.87 | 2019 | |
| Abbvie INC. | $15.00 | 2024 | |
| Pfizer INC. | $14.97 | 2025 | |
| Phadia US INC. | $14.07 | 2019 | |
| Inogen, INC. | $9.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.